ReviewJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2011
Barrett's esophagus: a review of the literature.
Review in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Diagnosis and Management of Barrett's Esophagus.Journal of clinical medicine · 2023Review
- Cellular barcoding to decipher clonal dynamics in disease.Science (New York, N.Y.) · 2022Review
- Novel Long Noncoding RNA miR205HG Functions as an Esophageal Tumor-Suppressive Hedgehog Inhibitor.Cancers · 2021Article
- Oesophageal Adenocarcinomas: Where Do We Stand Today?Cancers · 2020Article
- Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis.European journal of epidemiology · 2017Article
- Evolving management of metaplasia and dysplasia in Barrett's epithelium.World journal of gastroenterology · 2016Review
- An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling.Gastroenterology · 2015Article
- Dysplastic Barrett's esophagus.World journal of surgery · 2015Article
- A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma.Best practice & research. Clinical gastroenterology · 2015Review
- Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.Carcinogenesis · 2014Article
- Article
- Face Barrett's: esophageal adenocarcinoma affects the young.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2014Article
- Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.Oncogene · 2014Article
- Proton Pump Inhibitors: The Culprit for Barrett's Esophagus?Frontiers in oncology · 2014Review
- Glutathione Peroxidase 7 Suppresses Bile Salt-Induced Expression of Pro-Inflammatory Cytokines in Barrett's Carcinogenesis.Journal of Cancer · 2014Article
- Magnifying endoscopy for the diagnosis of specialized intestinal metaplasia in short-segment Barrett's esophagus.World journal of gastroenterology · 2013Article
- A cross-sectional analysis of the prevalence of Barrett esophagus in otolaryngology patients with laryngeal symptoms.Journal of clinical gastroenterology · 2013Article
- Upper gastrointestinal cancer and reflux disease.Journal of gastric cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barrett's esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia of the tubular esophagus that results from chronic gastroesophageal reflux. Which patients are at risk of having BE and which are at further risk of developing EAC has yet to be fully established. Many aspects of the management of BE have changed considerably in the past 5 years alone. The aim of this review is to define the critical elements necessary to effectively manage individuals with BE. The general prevalence of BE is estimated at 1.6-3% and follows a demographic distribution similar to EAC. Both short-segment (<3 cm) and long-segment (≥3 cm) BE confer a significant risk for EAC that is increased by the development of dysplasia. The treatment for flat high-grade dysplasia is endoscopic radiofrequency ablation therapy. The benefits of ablation for non-dysplastic BE and BE with low-grade dysplasia have yet to be validated. By understanding the intricacies of the development, screening, surveillance, and treatment of BE, new insights will be gained into the prevention and early detection of EAC that may ultimately lead to a reduction in morbidity and mortality in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.